FDA peptide reclassification: what it means for research

Introduction

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. appeared on the Joe Rogan Experience podcast and announced that approximately 14 previously restricted peptides would return to legal compounding status in the United States.

The reaction was predictable: biohacking forums lit up, cautious researchers raised eyebrows, and compounding pharmacies started fielding calls. But the real question isn’t whether BPC-157 will be legal to compound again. It’s what this shift means for the science, and whether the regulatory framework can keep pace with a market that’s been operating in grey areas for years.

Background: How Did These Peptides Get Restricted?

The story starts before 2023, but that’s when things came to a head. The FDA maintains a “bulks list” — a classification system for substances compounding pharmacies can legally use. Category 1 includes approved or well-studied substances. Category 2 lists those the FDA considers to have “safety concerns” or insufficient basis for compounding.

In September 2023, the FDA moved 19 peptides to Category 2, citing “risk for immunogenicity, peptide-related impurities, and limited safety-related information.” The affected compounds included BPC-157, TB-500, AOD-9604, CJC-1295, Ipamorelin, GHK-Cu, MOTS-c, and others that had become popular in sports medicine and anti-aging circles.

The FDA’s reasoning was scientifically defensible — most of these peptides genuinely lack robust human clinical data. But the move also shut down a substantial compounding market overnight, pushing demand toward unregulated online suppliers. Kennedy himself later acknowledged the ban “created the gray market.”

A Regulatory Timeline

It helps to see how we got here:

• 2021–2023: The FDA progressively adds 19 peptides to the Category 2 list, restricting compounding pharmacies from producing them.
• September 2023: The bulk Category 2 placement takes effect. Compounding pharmacies can no longer legally prepare BPC-157, TB-500, and others.
• December 2024: The FDA issues warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research for selling semaglutide, tirzepatide, and retatrutide as unapproved drugs.
• June 2025: FDA enforcement escalates — Amino Asylum’s warehouse is raided, taking the site offline.
• March 2026: Peptide Sciences, one of the largest US-based research peptide suppliers, voluntarily shuts down. The timing — shortly after receiving an earlier FDA warning letter — strongly suggests regulatory pressure.
• February 27, 2026: Kennedy announces on the Joe Rogan Experience that roughly 14 of the 19 restricted peptides will return to Category 1.
• As of March 2026: No formal FDA regulatory action has been published.

What Kennedy Actually Announced

On the podcast, Kennedy called the original reclassification of these 19 peptides “illegal” and announced that around 14 would return to legal compounding status. He admitted most lack robust human clinical data but framed the move as restoring legitimate research access.

As of March 5, 2026, no formal FDA regulatory action has been published to implement this change.

This distinction matters. Kennedy’s announcement is policy intent, not law. Compounding pharmacies remain bound by existing Category 2 restrictions until a formal change appears in the Federal Register.

• Watch for a formal Federal Register notice from the FDA
• Look for any conditions attached — Kennedy mentioned the FDA might require studies before full approval
• Monitor Congressional responses, as some legislators may seek to formalise or challenge the change

The 14 Peptides: What’s Likely Coming Back

The official list hasn’t been published, but based on Kennedy’s statements and industry analysis, the peptides expected to move from Category 2 back to Category 1 include:

Industry analysts suggest the five peptides most likely to remain restricted are those with weaker safety profiles or stronger adverse event signals: Melanotan II, GHRP-2, Cathelicidin LL-37, Ipamorelin, and GHRP-6. Though even this is speculative until the formal announcement.

The BPC-157 Evidence: What We Actually Know

BPC-157 is the poster child of this reclassification debate, so it’s worth being specific about the evidence.

It’s a 15-amino acid synthetic peptide derived from a protein in human gastric juice, first studied by Predrag Sikiric and his team at the University of Zagreb in the 1990s. They have over 100 preclinical publications covering tendon, ligament, and muscle healing; gastrointestinal protection; neurological effects; and cardiovascular research.

A 2025 systematic review (Vasireddi et al.) assessed 36 studies — 35 preclinical and one small clinical study of 12 patients with knee pain. The preclinical results were consistently positive across tissue types. The human data is barely a starting point.

There are no large-scale human trials for BPC-157. Most research comes from a single group, limiting independent replication. Long-term human safety data doesn’t exist. STAT News quoted the lead author of the systematic review stating BPC-157 “should not be used by humans” outside of clinical trials.

The bottom line: the preclinical research is genuinely interesting. The human research pipeline is just getting started. Regulatory changes alter who can access these compounds, but they don’t change what we know about them.

What This Means for UK Researchers

This is a US regulatory story, and UK researchers operate under a different framework. But it matters here for a few reasons:

First, the US compounding market is the largest in the world. If these peptides return to Category 1, the volume of compounded peptides in circulation will increase substantially, which affects global supply chains and manufacturing quality standards.

Second, the UK’s MHRA takes a different approach to peptide regulation. Research-grade peptides sold for laboratory use remain accessible in the UK regardless of US compounding status. But any shift in US clinical trial activity around these peptides will eventually influence UK research priorities and regulatory thinking.

Third, if Kennedy’s reclassification leads to mandated human studies — which he hinted at on the podcast — the resulting data would benefit researchers everywhere. The biggest gap in the peptide literature isn’t preclinical evidence; it’s the near-total absence of well-designed human trials. Anything that accelerates those trials is good for the field.

What This Means for the Research Community

For researchers, a few practical implications:

1. Broader access may follow, but isn’t immediate. If formal regulatory changes occur, compounding pharmacies can supply these peptides again, expanding access for research. But this hasn’t happened yet.
2. Supply quality will matter more, not less. Regulatory shifts tend to attract new suppliers, not all of whom prioritise purity and testing. Researchers should verify supply chain integrity regardless of regulatory status.
3. The evidence gap still needs filling. Kennedy’s announcement is regulatory, not scientific. The field needs well-designed human trials. The change might create conditions for better research if it reduces previous deterrents.
4. Watch for conditions attached to reclassification. Requirements for safety studies before full compounding approval could accelerate human evidence gathering — which would benefit everyone.

Related articles on Amino Research

• BPC-157 in Musculoskeletal Research: What a Systematic Review Shows
• The Peptide Boom: Why the Market Is Doubling by 2033
• CJC-1295: A Complete Research Guide
• GLP-1 Peptides: Beyond Weight Loss — The Longevity Case

A Note on Quality and Research Integrity

All Amino Research products are for laboratory use only. Regardless of regulatory status, the principles of responsible research remain:

• Use verified, HPLC-tested research peptides with documented CoAs
• Follow established research protocols
• Engage with peer-reviewed literature instead of relying on anecdotes
• Acknowledge what’s known and what’s not